​​​​​​​The Order of the Minister of Health “On Approval of the Regulation on the Procedure for Conducting Clinical Trials of Pharmacological and Medicinal Products” has been officially registered with the Ministry of Justice (registration No. 3745 dated 6 January 2026).

​​​​​​​By Order of the Minister of Health dated 28 November 2025 No. 367, comprehensive measures have been approved to align technical requirements for pharmaceutical products and medical devices with leading international standards.

​​​​​​​By Order of the Minister of Health dated 22 December 2025 No. 27,“On Approval of the Regulation on the Procedure for Conducting Clinical Investigations of Medical Devices,” the document was officially registered with the Ministry of Justice (registration No. 3746 dated 7 January 2026).

Dear employees of the Prosecutor’s Office and esteemed veterans, The staff of the Center for the Safety of Pharmaceutical Products sincerely congratulates you on your professional holiday — the Day of Employees of the Prosecutor’s Office of the Republic of Uzbekistan.

The results of 2025 demonstrated increased activity in the regulation of medical devices within the work of the Committee for New Medical Technology. In particular, the expansion of expert review activities, acceleration of document processing procedures, and the broadening of international cooperation indicate a qualitative renewal of management and assessment approaches in this sector.

​​​​​​​The Order of the Minister of Health “On Amendments and Additions to the Rules for Certification of Pharmaceutical Products” has been registered with the Ministry of Justice of the Republic of Uzbekistan (Registration No. 3386-2 dated December 25, 2025).

As part of the implementation of the Action Plan for the 2024–2025 National Program aimed at executing the National Strategy to Combat Drug Abuse and Drug-Related Crime in the Republic of Uzbekistan, the results of 2025 summarized by the Committee for Drug Control demonstrated a fundamental renewal of approaches in this area. The digitalization of control mechanisms, strengthening of licensing requirements, and implementation of preventive measures at the regional level indicate the formation of a systemati

According to the results of quality control and stability testing conducted by the manufacturer, a deviation from the established specifications was identified in batch C2501976 of the medicinal product “Telsartan H 80 mg / 12.5 mg”, specifically with regard to the content of the active substance hydrochlorothiazide. This deviation has been assessed as a quality non-conformity.

2026 yilning 23-27 fevral kunlari Farmatsevtika mahsulotlari xavfsizligi markazi USP bilan hamkorlikda hamda ICH ko‘magida "Klinik tadqiqotlarda shaffoflik, xavfsizlik va ilmiy qat’iylikni oshirishda xalqaro uyg‘unlashgan yondashuvlardan foydalanish" mavzusida seminar trening o'tkazishni rejalashtirmoqda.

2025 yil davomida Farmakopeya qo‘mitasi huzuridagi Ilmiy va ekspertlar kengashi tomonidan dori vositalari muomalasini tartibga solish bo‘yicha izchil ishlar amalga oshirildi.